Recent Updates
Recently added Catalysts
NBIX Positive Sentiment

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as...

Friday, April 4, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Neurocrine Biosciences has appointed Dr. Sanjay Keswani as Chief Medical Officer, effective June 2, 2025. Dr. Keswani, an experienced physician-scientist with over 20 years in the pharmaceutical industry, will oversee clinical development and medical affairs. He succeeds Dr. Eiry W. Roberts, who will transition to a strategic advisory role.
Price reaction · baseline $102.88 (2025-04-03 close) · hit after-hours · clean, no other NBIX news in the window
day 0 close
-7%
day 1 · peak
-9.4%
day 3
-7.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Sanjay Keswani brings over 20 years of industry experience.
  • His appointment strengthens Neurocrine's executive management team.
  • He will lead clinical development and medical affairs activities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
3.5%
average across 4 past catalysts
Lead asset
NBI-6024
Phase 1 · Type 1 Diabetes Mellitus

Full Press Release Details

• Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas
SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the appointment of Sanjay Keswani , M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025 . Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years and who will remain with Neurocrine in a strategic advisory role.

Frequently Asked Questions

Who is the new Chief Medical Officer of Neurocrine?

Dr. Sanjay Keswani has been appointed as the Chief Medical Officer.

When will Dr. Keswani start his role at Neurocrine?

Dr. Keswani will assume his role on June 2, 2025.

What experience does Dr. Keswani bring to Neurocrine?

He has over 20 years of pharmaceutical industry experience.

Who did Dr. Keswani succeed at Neurocrine?

He succeeds Dr. Eiry W. Roberts, who will remain in an advisory role.

ShareAdd on Google
Tags: NBIX Viatris Investor Conferences Healthcare Neurocrine Biosciences Sanjay Keswani Chief Medical Officer Eiry W. Roberts pharmaceutical industry
Last updated: Apr 4, 2025

Biotech snapshot

Cash runway
$482M liquidity · $0M/mo burn
Low dilution risk
Lead asset
NBI-6024Phase 1
Type 1 Diabetes Mellitus →

Catalyst track record

+37%
best trade around NBIX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NBIX.

See every catalyst's timing & PoA →